Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Malignant lymphoma of the conjunctiva

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

APA

CBE

MLA

Vancouver

Author

Kirkegaard, Marina M ; Coupland, Sarah E ; Prause, Jan U ; Heegaard, Steffen. / Malignant lymphoma of the conjunctiva. In: Survey of Ophthalmology. 2015 ; Vol. 60, No. 5. pp. 444-58.

Bibtex

@article{33d6c0341df04d20bd8c04037f7591b1,
title = "Malignant lymphoma of the conjunctiva",
abstract = "Conjunctival lymphomas constitute 25{\%} of all ocular adnexal lymphomas. The majority are B-cell non-Hodgkin lymphomas (NHLs) (98{\%}), whereas conjunctival T-cell NHLs are rare (2{\%}). The most frequent subtype of conjunctival B-cell lymphoma is extranodal marginal zone lymphoma (EMZL; 81{\%}), followed by follicular lymphoma (8{\%}), diffuse large B-cell lymphoma (3{\%}), and mantle cell lymphoma (3{\%}). Extranodal marginal zone lymphoma occurs slightly more often in women and, along with follicular lymphoma, presents late in the seventh decade of life, whereas diffuse large B-cell lymphoma and especially mantle cell lymphoma have a predilection for the male gender and typically present in the eighth decade. Extranodal marginal zone lymphoma and follicular lymphoma present most frequently in the forniceal and bulbar conjunctiva. Conjunctival diffuse large B-cell lymphoma, mantle cell lymphoma and T-cell NHLs are characterized by a short duration of symptoms before the first ophthalmologic consultation. External beam radiotherapy is the treatment of choice for extranodal marginal zone lymphoma and follicular lymphoma, whereas diffuse large B-cell lymphoma, mantle cell lymphoma, and T-cell NHLs are mainly treated with chemotherapy. Conjunctival T-cell NHLs are associated with a particularly poor prognosis, with 50{\%} of patients having progression or recurrence during a 1-year follow-up period.",
author = "Kirkegaard, {Marina M} and Coupland, {Sarah E} and Prause, {Jan U} and Steffen Heegaard",
note = "Copyright {\circledC} 2015 Elsevier Inc. All rights reserved.",
year = "2015",
month = "5",
day = "25",
doi = "10.1016/j.survophthal.2015.05.001",
language = "English",
volume = "60",
pages = "444--58",
journal = "Survey of Ophthalmology",
issn = "0039-6257",
publisher = "Elsevier Inc",
number = "5",

}

RIS

TY - JOUR

T1 - Malignant lymphoma of the conjunctiva

AU - Kirkegaard, Marina M

AU - Coupland, Sarah E

AU - Prause, Jan U

AU - Heegaard, Steffen

N1 - Copyright © 2015 Elsevier Inc. All rights reserved.

PY - 2015/5/25

Y1 - 2015/5/25

N2 - Conjunctival lymphomas constitute 25% of all ocular adnexal lymphomas. The majority are B-cell non-Hodgkin lymphomas (NHLs) (98%), whereas conjunctival T-cell NHLs are rare (2%). The most frequent subtype of conjunctival B-cell lymphoma is extranodal marginal zone lymphoma (EMZL; 81%), followed by follicular lymphoma (8%), diffuse large B-cell lymphoma (3%), and mantle cell lymphoma (3%). Extranodal marginal zone lymphoma occurs slightly more often in women and, along with follicular lymphoma, presents late in the seventh decade of life, whereas diffuse large B-cell lymphoma and especially mantle cell lymphoma have a predilection for the male gender and typically present in the eighth decade. Extranodal marginal zone lymphoma and follicular lymphoma present most frequently in the forniceal and bulbar conjunctiva. Conjunctival diffuse large B-cell lymphoma, mantle cell lymphoma and T-cell NHLs are characterized by a short duration of symptoms before the first ophthalmologic consultation. External beam radiotherapy is the treatment of choice for extranodal marginal zone lymphoma and follicular lymphoma, whereas diffuse large B-cell lymphoma, mantle cell lymphoma, and T-cell NHLs are mainly treated with chemotherapy. Conjunctival T-cell NHLs are associated with a particularly poor prognosis, with 50% of patients having progression or recurrence during a 1-year follow-up period.

AB - Conjunctival lymphomas constitute 25% of all ocular adnexal lymphomas. The majority are B-cell non-Hodgkin lymphomas (NHLs) (98%), whereas conjunctival T-cell NHLs are rare (2%). The most frequent subtype of conjunctival B-cell lymphoma is extranodal marginal zone lymphoma (EMZL; 81%), followed by follicular lymphoma (8%), diffuse large B-cell lymphoma (3%), and mantle cell lymphoma (3%). Extranodal marginal zone lymphoma occurs slightly more often in women and, along with follicular lymphoma, presents late in the seventh decade of life, whereas diffuse large B-cell lymphoma and especially mantle cell lymphoma have a predilection for the male gender and typically present in the eighth decade. Extranodal marginal zone lymphoma and follicular lymphoma present most frequently in the forniceal and bulbar conjunctiva. Conjunctival diffuse large B-cell lymphoma, mantle cell lymphoma and T-cell NHLs are characterized by a short duration of symptoms before the first ophthalmologic consultation. External beam radiotherapy is the treatment of choice for extranodal marginal zone lymphoma and follicular lymphoma, whereas diffuse large B-cell lymphoma, mantle cell lymphoma, and T-cell NHLs are mainly treated with chemotherapy. Conjunctival T-cell NHLs are associated with a particularly poor prognosis, with 50% of patients having progression or recurrence during a 1-year follow-up period.

U2 - 10.1016/j.survophthal.2015.05.001

DO - 10.1016/j.survophthal.2015.05.001

M3 - Journal article

VL - 60

SP - 444

EP - 458

JO - Survey of Ophthalmology

JF - Survey of Ophthalmology

SN - 0039-6257

IS - 5

ER -

ID: 45983191